The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Dec 20, 2022

Keywords

ClinConnect Summary

This is a single-center, open-ended, single-arm clinical study to evaluate the effectiveness of daily ursodeoxycholic acid plus routine protective measures for the prevention of novel coronavirus infection. The target sample size is 130 medical workers and each healthy volunteer will be followed weekly for nucleic acid/antigen testing or disease progression over an 8-week period for new crown infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 - 65 years old.
• • 2. No restriction on gender.
• • 3. Medical-related personnel (working hours \>20 hours per week) serving during the COVID-19 outbreak, including physicians, nurses, medical technicians, administrators, and medical students
• • 4. COVID-19 nucleic acid test negative within 48 hours
• • 5. Sign the informed consent form
• Exclusion Criteria:
• • 1. Exhibit COVID-19 symptoms, including fever, muscle pain, headache, cough, sore throat, and loss of smell and taste
• • 2. Previous infection with novel coronavirus within 6 months
• • 3. Previous (past 30 days), current or planned (during the study period) use of immunomodulatory-related drugs
• • 4. Those with allergy or intolerance to ursodeoxycholic acid, gallbladder or bile duct disease, severe liver failure, or liver function impairment
• • 5. Pregnancy and lactation
• • 6. Use of drugs with which ursodeoxycholic acid is contraindicated
• • 7. Other reported health conditions that make participation in the study not in the best interest of the individual